基因沉默市场（2026—2031）
基因沉默市场规模预计由2026年的126.6亿美元增至2031年的228.1亿美元，预测期复合年增长率为12.50%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
基因沉默市场规模预计由2026年的126.6亿美元增至2031年的228.1亿美元，预测期复合年增长率为12.50%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 12.5% | 机构预测 |
| 市场规模 | 2026 | USD 12.66 billion | 机构预测 |
| 市场规模 | 2031 | USD 22.81 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | drug discovery & development | 2025 | 55.450% |
| end_user | pharmaceutical & biotechnology companies | 2025 | 42.670% |
| geography | North America | 2025 | 41.750% |
| product_and_service | products | 2025 | 79.890% |
关键结论
- application 维度中，drug discovery & development 在 2025 年的公开份额为 55.45%。
- end_user 维度中，pharmaceutical & biotechnology companies 在 2025 年的公开份额为 42.67%。
- geography 维度中，North America 在 2025 年的公开份额为 41.75%。
- product_and_service 维度中，products 在 2025 年的公开份额为 79.89%。
主要参与者
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Merck KGaA
- Thermo Fisher Scientific Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Expansion of approved RNai and antisense therapeutics | +3.000% | Global, concentrated in North America and Europe | Short term (≤ 2 years) |
| Genomic diagnosis of previously undruggable targets | +1.500% | Global, with early gains in North America and East Asia | Medium term (2-4 years) |
| Advances in galnac and lipid nanoparticle delivery | +2.500% | Global, with hepatic delivery maturing and extrahepatic delivery emerging | Medium term (2-4 years) |
| Expansion into cardiometabolic and chronic diseases | +2.000% | North America, Europe, and high-income Asia-Pacific markets | Medium term (2-4 years) |
| AI-enabled design of silencing sequences and delivery systems | +1.200% | North America and Europe, with spillover to the Asia-Pacific | Long term (≥ 4 years) |
| Licensing demand for extrahepatic delivery platforms | +1.000% | North America, with early activity in East Asia and Europe | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Extrahepatic delivery and blood-brain barrier limitations | -2.000% | Global, most acute in neurology applications | Long term (≥ 4 years) |
| High treatment cost and payer reimbursement pressure | -1.800% | North America and Europe, with spillover to high-income Asia-Pacific | Medium term (2-4 years) |
| Innate immune activation and off-target silencing | -1.500% | Global, particularly in extrahepatic and central nervous system programs | Medium term (2-4 years) |
| Specialized manufacturing capacity and quality-control constraints | -1.000% | Global, with supply risk concentrated in North America and Europe | Medium term (2-4 years) |
报告关注的关键问题
What is driving demand for gene silencing therapies?
Demand is supported by more approved RNAi and antisense therapies, licensing activity, and expansion into cardiometabolic diseases.
How large is the Gene Silencing Market in 2026?
The Gene Silencing Market is valued at USD 12.66 billion in 2026 and is forecast to reach USD 22.81 billion by 2031.
Which product category leads gene silencing revenue?
Products led with 79.89% share in 2025 because approved RNAi and antisense medicines generate most commercial revenue.
Which application is growing the fastest?
Therapeutics Manufacturing is projected to grow at a 15.46% CAGR through 2031 as commercial and clinical production needs increase.
Which region is growing fastest for gene silencing?
Asia-Pacific is projected to grow at a 13.56% CAGR through 2031, supported by clinical development and licensing activity.
What limits broader use of gene silencing therapies?
Delivery beyond the liver, reimbursement conditions, treatment cost, and specialized manufacturing capacity remain key limitations.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence